To our knowledge, in the field of lung cancer research, Ba/F3 cells were first used for this purpose, that is, to confirm that the EGFR T790M secondary mutation conferred acquired resistance to gefitinib, a 1G‐EGFR‐TKI.25 This evidence concerns the gene EGFR and lung cancer.